This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/513560-merck-pasteur-coronavirus-vaccine/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Out of the race: US pharma giant Merck & French Pasteur Institute discontinue their Covid-19 vaccine candidates | Out of the race: US pharma giant Merck & French Pasteur Institute discontinue their Covid-19 vaccine candidates |
| (7 months later) | |
| With Pfizer, Moderna and Sputnik V shots being widely distributed since December, US pharma giant Merck and its partner Institut Pasteur in France have canceled their coronavirus vaccine projects due to low immune responses. | With Pfizer, Moderna and Sputnik V shots being widely distributed since December, US pharma giant Merck and its partner Institut Pasteur in France have canceled their coronavirus vaccine projects due to low immune responses. |
| Merck, known as MSD outside North America, said on Monday that it was discontinuing the development of two of its vaccine candidates. | Merck, known as MSD outside North America, said on Monday that it was discontinuing the development of two of its vaccine candidates. |
| The decision was made after the results of Phase 1 clinical trials revealed that the immune responses produced by the candidates were inferior to those found in people who were cured from the coronavirus, as well as in rivaling vaccines. | The decision was made after the results of Phase 1 clinical trials revealed that the immune responses produced by the candidates were inferior to those found in people who were cured from the coronavirus, as well as in rivaling vaccines. |
| “We are grateful to our collaborators who worked with us on these vaccine candidates and to the volunteers in the trials,” Dr. Dean Y. Li, the head of Merck Research Laboratories, said. | “We are grateful to our collaborators who worked with us on these vaccine candidates and to the volunteers in the trials,” Dr. Dean Y. Li, the head of Merck Research Laboratories, said. |
| The US company will now focus its efforts on two therapeutic candidates it had been developing, while also continuing research into the virus, which has already infected over 99 million and killed more than 2.1 million people around the globe. | The US company will now focus its efforts on two therapeutic candidates it had been developing, while also continuing research into the virus, which has already infected over 99 million and killed more than 2.1 million people around the globe. |
| One of the canceled candidates was developed by Merck together with Paris-based French Institut Pasteur, which also confirmed that their work on the project has been scrapped. | One of the canceled candidates was developed by Merck together with Paris-based French Institut Pasteur, which also confirmed that their work on the project has been scrapped. |
| The immunization that was based on a vaccine against measles had been in trials since early August. It was never a part of the French government’s vaccination program. | The immunization that was based on a vaccine against measles had been in trials since early August. It was never a part of the French government’s vaccination program. |
| Institut Pasteur will continue with its two other vaccine projects – one designed for nasal distribution and the other being DNA-based. However, both of them are only in the preclinical stage. | Institut Pasteur will continue with its two other vaccine projects – one designed for nasal distribution and the other being DNA-based. However, both of them are only in the preclinical stage. |
| Like this story? Share it with a friend! | Like this story? Share it with a friend! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |